Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.addr.2015.01.007 http://scihub22266oqcxt.onion/10.1016/j.addr.2015.01.007 C4504743!4504743!25666164     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Drug+Deliv+Rev 2015 ; 87 (ä): 108-19 Nephropedia Template TP {{tp|p=25666164|t=2015. Preclinical and clinical development of siRNA-based therapeutics |pdf=|usr=}}{{25666164}} gab.com Text Preclinical and clinical development of siRNA-based therapeutics JO: Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=25666164 #FOAvip Discovery of RNA interference, first in plants and C. elegans and later in mammalian cells, led to the emergence of a transformative view in biomedical research. Knowledge of the multiple actions of non-coding RNAs has truly allowed viewing DNA, RNA and proteins in novel ways. Small interfering RNAs (siRNAs) can be used as tools to study single gene function both in vitro and in vivo and are an attractive new class of therapeutics, especially against undruggable targets for the treatment of cancer and other diseases. Despite the potential of siRNAs in cancer therapy, many challenges remain, including rapid degradation, poor cellular uptake and off-target effects. Rational design strategies, selection algorithms, chemical modifications and nanocarriers offer significant opportunities to overcome these challenges. Here, we review the development of siRNAs as therapeutic agents from early design to clinical trial, with special emphasis on the development of EphA2-targeting siRNAs for ovarian cancer treatment. Twit Text FOAVip Preclinical and clinical development of siRNA-based therapeutics ????Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=25666164 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25666164 #FOAvip English Wikipedia <ref>{{Cite pmid|25666164}}</ref> Preclinical and clinical development of siRNA-based therapeutics #MMPMID25666164 Ozcan G; Ozpolat B; Coleman RL; Sood AK; Lopez-Berestein G Adv Drug Deliv Rev 2015[Jun]; 87 (ä): 108-19 PMID25666164show ga Discovery of RNA interference, first in plants and C. elegans and later in mammalian cells, led to the emergence of a transformative view in biomedical research. Knowledge of the multiple actions of non-coding RNAs has truly allowed viewing DNA, RNA and proteins in novel ways. Small interfering RNAs (siRNAs) can be used as tools to study single gene function both in vitro and in vivo and are an attractive new class of therapeutics, especially against undruggable targets for the treatment of cancer and other diseases. Despite the potential of siRNAs in cancer therapy, many challenges remain, including rapid degradation, poor cellular uptake and off-target effects. Rational design strategies, selection algorithms, chemical modifications and nanocarriers offer significant opportunities to overcome these challenges. Here, we review the development of siRNAs as therapeutic agents from early design to clinical trial, with special emphasis on the development of EphA2-targeting siRNAs for ovarian cancer treatment. äPreclinical and clinical development of siRNA-based therapeutics (epmc).pdf DeepDyve Pubget Overpricing